Congress Targets Pharmacy Benefit Managers, Risks Higher Drug Costs

Congress is on a mission to lower drug prices, but recent legislative moves suggest they might be shooting themselves in the foot. The 2026 Consolidated Appropriations Act, ostensibly designed to bring down prescription costs, could paradoxically make them soar instead. The numbers tell the story.

The Timeline: From Promise to Policy

President Trump and the Republican Congress have consistently highlighted their commitment to reducing prescription drug prices. From the early days of Trump's presidency, the administration has publicly targeted drug costs as a major issue. The reality is, though, that the Consolidated Appropriations Act of 2026 includes provisions that could have the opposite effect.

At the center of this legislative quagmire are Pharmacy Benefit Managers (PBMs), the intermediaries between pharmacies and insurance companies. These entities have been using their use to negotiate lower drug prices for decades, employing a dual strategy that has kept prices in check. However, as the new law unfolds, it proposes transforming these hard-bargaining negotiators into mere administrators. The legislation passed the House on January 14, 2026, before moving to the Senate, and its implications began surfacing shortly thereafter.

Impact: A Shift in Power Dynamics

So, what changes with this new legislation? Here’s what matters: the bill decouples PBM compensation from manufacturer rebates in Medicare, requiring a flat fee arrangement instead. This move may seem fair, yet it fundamentally shifts the incentives that once encouraged aggressive bargaining.

If PBMs are no longer rewarded for securing better terms, their negotiating power with pharmaceutical companies could diminish. This shift might sound benign, but by weakening the middlemen, the bill inadvertently strengthens the hand of pharmaceutical firms. In a market where prices are negotiated, eliminating strong intermediaries can lead to higher prices. And the twist? The bill also broadens the 'any willing pharmacy' clause, forcing PBMs to work with any pharmacy willing to meet standardized terms. This inclusivity sounds consumer-friendly but dilutes the PBM's ability to drive prices down by steering volume toward more cost-effective outlets.

Pharmaceutical companies, meanwhile, stand to benefit the most. With PBMs neutered, manufacturers will likely face less pressure to lower prices, potentially leading to increased revenues. But who pays the price for this policy misstep? Primarily seniors on Medicare and small businesses providing health benefits. Without the bargaining power of PBMs, these groups will face higher costs.

Outlook: Navigating the Potential Fallout

What’s next on the horizon? Lawmakers have put themselves in a tricky spot, where they must reconcile public promises with policy outcomes. The goal to reduce drug pricing clashes with the reality that this new structure could inflate it. So, where do they go from here?

Strengthening the competitive market would be a start. Instead of regulatory shackles, empowering PBMs to push for better deals could be key. But will Congress pivot? The answer lies in how they respond to the market's inevitable backlash when costs climb instead of fall.

From a risk perspective, the crypto world can draw a parallel. Unintended consequences of regulatory shifts aren't foreign. As governments globally eye crypto regulation, the lesson here's to craft policies that genuinely enhance market efficiency rather than stifle it.

For now, the ball is in Congress's court. Lowering drug prices demands more than just legislation. It requires a reliable strategy that acknowledges the roles of all stakeholders, including those less visible intermediaries. If lessons are learned and plans adjusted, there’s a chance for a genuine reduction in drug costs. If not? The burden falls back on those who can least afford it.